Cargando…
ICER's timelines for assessments extended due to COVID-19
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140250/ https://www.ncbi.nlm.nih.gov/pubmed/32288506 http://dx.doi.org/10.1007/s40274-020-6689-5 |
Ejemplares similares
-
ICER update to pricing models of remdesivir for COVID-19
Publicado: (2020) -
ICER's second update to pricing models of remdesivir for COVID-19
Publicado: (2020) -
ICER publishes draft scoping report on COVID-19 treatments
Publicado: (2021) -
ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020) -
HTA assessment of COVID-19 interventions in Ireland
Publicado: (2020)